Publications by authors named "Veronica Molina Barcena"
A randomized, double-blind study on the efficacy of oral domperidone versus placebo for reducing SARS-CoV-2 viral load in mild-to-moderate COVID-19 patients in primary health care.
Alejandro Rabanal Basalo Mercedes Navarro Pablos Nuria Viejo Pinero María Luz Vila Méndez Verónica Molina Barcena
Ann Med
October 2023
Introduction: The clinical effect of domperidone against COVID-19 has been investigated in a double-blind phase III clinical trial (EudraCT number 2021-001228-17). Domperidone has shown in vitro antiviral activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and potential immudolatory properties through the stimulation of prolactin secretion.
Patients And Methods: The efficacy of oral domperidone plus standard of care (SOC; = 87) versus placebo plus SOC ( = 86) was evaluated in a 28-day randomized double-blind multicentre study in primary health care centres.
Efficacy of Bromhexine versus Standard of Care in Reducing Viral Load in Patients with Mild-to-Moderate COVID-19 Disease Attended in Primary Care: A Randomized Open-Label Trial.
María Luz Vila Méndez Carmen Antón Sanz Alicia Del Rocío Cárdenas García Amparo Bravo Malo Francisco Javier Torres Martínez Verónica Molina Barcena
J Clin Med
December 2022
Article Synopsis
- A 28-day study tested the effectiveness of bromhexine combined with standard care against standard care alone in treating 191 outpatients with mild to moderate COVID-19.
- Both treatment groups showed a similar reduction in viral load (measured by specific gene thresholds) over the study period, with no significant differences between them.
- Overall, the study concluded that bromhexine did not significantly enhance viral load reduction compared to standard care alone, suggesting it might not be a beneficial antiviral for COVID-19 patients.